Results 151 to 160 of about 56,601 (283)

Maintenance intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: trends from an Australian tertiary centre

Internal Medicine Journal, EarlyView.
Abstract Background Chronic inflammatory demyelinating polyneuropathy (CIDP) is commonly treated with long‐term intravenous immunoglobulin (IVIg). Individual dosing requirements and duration of IVIg differ among patients, leading to significant heterogeneity in IVIg utilisation.
Kristina T. Pidd, Anthony Khoo
wiley   +1 more source

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Polycaprolactone/graphene oxide/acellular matrix nanofibrous scaffolds with antioxidant and promyelinating features for the treatment of peripheral demyelinating diseases. [PDF]

J Mater Sci Mater Med, 2023
Nagarajan A, Rizwana N, Abraham M, Bhat M, Vetekar A, Thakur G, Chakraborty U, Agarwal V, Nune M.   +8 more
europepmc   +1 more source

Integrative methylation and miRNA dysregulation in dlPFC reveal distinct molecular signatures of suicide and non‐suicide subtypes in major depressive disorder

Psychiatry and Clinical Neurosciences, EarlyView.
Aim Major depressive disorder (MDD) is a leading cause of disability and carries a high risk of suicide. MicroRNAs (miRNAs) are epigenetic regulators implicated in MDD and can be regulated by DNA methylation, potentially reshaping downstream gene networks.
Aleena Francis, Yogesh Dwivedi
wiley   +1 more source

Distinct features of B cell receptors in neuromyelitis optica spectrum disorder among CNS inflammatory demyelinating diseases. [PDF]

J Neuroinflammation, 2023
Kim HJ, Park JE, Shin W, Seo D, Kim S, Kim H, Noh J, Lee Y, Kim H, Lim YM, Kim H, Lee EJ.   +11 more
europepmc   +1 more source

Microglial PD-1/PD-L1 axis in CNS demyelinating diseases: a dual immunoregulatory perspective. [PDF]

Front Cell Neurosci
Zhou M, Yao X, Liu L, Gao Y, Chen W, Zheng K, Li H, Meng Q.   +7 more
europepmc   +1 more source

Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases

Experimental Physiology, EarlyView.
Abstract Klotho, a pleiotropic protein initially identified for its role in kidney function, has garnered significant attention for its neuroprotective properties in various neurodegenerative diseases. It regulates key processes, such as oxidative stress, neuroinflammation, synaptic plasticity and myelination, all crucial for maintaining neuronal ...
Amir Arsalan Ghahari, Leylinaz Safaeihavadaragh, Mehrdad Nourizadeh, Shaghayegh Davari, Saba Safaei, Farshad Zare, Safa Alkayyat, Erfan Kamali Far   +7 more
wiley   +1 more source

A Five-Year Retrospective Study: Relationship Between Cervical Spine Whiplash Injuries and Demyelinating Diseases in the Pediatric Population. [PDF]

Cureus
Kardouh MS, Van Wagoner C, Coleman J, Saleh E.   +3 more
europepmc   +1 more source

Short-term safety of inactivated SARS-Cov-2 vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases. [PDF]

Vaccine X, 2023
Zhao D, Zhang W, Ma X, Zhao R, Yao L, Lu J, Yan X, Bai M, Zhang G, Li H, Guo J.   +10 more
europepmc   +1 more source

A Rare Overlap of AQP4 and MOG Seropositivity in Neuromyelitis Optica Spectrum Disorder: A Case Report

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is an immune‐mediated disorder of the central nervous system associated with autoantibodies against aquaporin‐4 (AQP4). This is distinct from myelin‐oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), defined by anti‐MOG antibodies.
Sarah E. Butler, Siew Kar Chen, Mastura Monif   +2 more
wiley   +1 more source